OTO Fertility, a division of Canada-based OTO Coach, has launched a platform combining a clinical-grade wearable biosensor with an FDA-approved app designed to help predict fertility treatment outcomes.
The system monitors more than 50 biometric markers including heart rate variability, nervous system regulation, and stress response to identify when the body is in what the company calls an optimized “Fertility Zone.” OTO claims its Fertility Index is a more accurate indicator of pregnancy success than standard measurements including age, BMI, or AMH.
The technology draws on bioscience and space medicine research originally developed by NASA for astronauts and later adapted for elite athletes.
“Until now, there’s been no accurate way to predict fertility outcomes based on what’s actually happening in the body in real time,” said Caleb Evans, CEO and founder of OTO. “Our solution gives patients a clear understanding of their body’s signals, restores agency, and peace of mind, and provides clinicians with a powerful new layer of insights to guide better outcomes. OTO doesn’t replace existing fertility protocols; it enhances them. And for the millions who have done everything right and still struggle to get pregnant, it can help unlock a path forward.”
OTO is positioning its platform as a tool to help patients and clinicians reduce poorly-timed interventions and provide physiological context for treatment decisions. The tool is designed to support both patients tracking independently and fertility clinics looking to integrate biometric data into their protocols.
